PRO-DEX INC (PDEX) Stock Fundamental Analysis
NASDAQ:PDEX - Nasdaq - US74265M2052 - Common Stock - Currency: USD
PDEX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. PDEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PDEX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make PDEX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year PDEX was profitable.
In the past year PDEX had a positive cash flow from operations.
Each year in the past 5 years PDEX has been profitable.
In multiple years PDEX reported negative operating cash flow during the last 5 years.
1.2 Ratios
PDEX has a better Return On Assets (9.59%) than 91.58% of its industry peers.
Looking at the Return On Equity, with a value of 16.87%, PDEX belongs to the top of the industry, outperforming 92.63% of the companies in the same industry.
The Return On Invested Capital of PDEX (15.13%) is better than 95.26% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PDEX is above the industry average of 8.09%.
The 3 year average ROIC (11.81%) for PDEX is below the current ROIC(15.13%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.59% | ||
| ROE | 16.87% | ||
| ROIC | 15.13% |
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
1.3 Margins
PDEX's Profit Margin of 9.17% is amongst the best of the industry. PDEX outperforms 84.21% of its industry peers.
PDEX's Profit Margin has declined in the last couple of years.
PDEX's Operating Margin of 14.71% is amongst the best of the industry. PDEX outperforms 85.26% of its industry peers.
PDEX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 28.25%, PDEX is doing worse than 76.84% of the companies in the same industry.
In the last couple of years the Gross Margin of PDEX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.71% | ||
| PM (TTM) | 9.17% | ||
| GM | 28.25% |
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PDEX is still creating some value.
Compared to 1 year ago, PDEX has less shares outstanding
Compared to 5 years ago, PDEX has less shares outstanding
Compared to 1 year ago, PDEX has an improved debt to assets ratio.
2.2 Solvency
PDEX has an Altman-Z score of 6.36. This indicates that PDEX is financially healthy and has little risk of bankruptcy at the moment.
PDEX's Altman-Z score of 6.36 is amongst the best of the industry. PDEX outperforms 81.58% of its industry peers.
The Debt to FCF ratio of PDEX is 2.10, which is a good value as it means it would take PDEX, 2.10 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PDEX (2.10) is better than 87.37% of its industry peers.
PDEX has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PDEX (0.36) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.1 | ||
| Altman-Z | 6.36 |
ROIC/WACC1.74
WACC8.7%
2.3 Liquidity
A Current Ratio of 3.41 indicates that PDEX has no problem at all paying its short term obligations.
The Current ratio of PDEX (3.41) is better than 62.11% of its industry peers.
A Quick Ratio of 1.94 indicates that PDEX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.94, PDEX is in line with its industry, outperforming 48.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 81.18% over the past year.
The Earnings Per Share has been decreasing by -6.76% on average over the past years.
PDEX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.00%.
PDEX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.66% yearly.
EPS 1Y (TTM)81.18%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%541.18%
Revenue 1Y (TTM)21%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%24.74%
3.2 Future
PDEX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 84.09% yearly.
Based on estimates for the next years, PDEX will show a quite strong growth in Revenue. The Revenue will grow by 12.93% on average per year.
EPS Next Y229.03%
EPS Next 2Y84.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.48%
Revenue Next 2Y12.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 27.14, the valuation of PDEX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of PDEX indicates a rather cheap valuation: PDEX is cheaper than 81.58% of the companies listed in the same industry.
PDEX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.42, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.89, which indicates a rather expensive current valuation of PDEX.
Based on the Price/Forward Earnings ratio, PDEX is valued cheaply inside the industry as 84.21% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 24.39. PDEX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.14 | ||
| Fwd PE | 19.89 |
4.2 Price Multiples
88.42% of the companies in the same industry are more expensive than PDEX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PDEX is valued cheaper than 91.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.25 | ||
| EV/EBITDA | 14.21 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PDEX may justify a higher PE ratio.
PDEX's earnings are expected to grow with 84.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y84.09%
EPS Next 3YN/A
5. Dividend
5.1 Amount
PDEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRO-DEX INC
NASDAQ:PDEX (1/28/2025, 8:00:00 PM)
41.79
+0.52 (+1.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners27.09%
Inst Owner Change2.29%
Ins Owners35.27%
Ins Owner Change2.38%
Market Cap136.24M
Analysts82.86
Price Target53.04 (26.92%)
Short Float %0.96%
Short Ratio0.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.2%
Min EPS beat(2)28.85%
Max EPS beat(2)153.55%
EPS beat(4)2
Avg EPS beat(4)18.71%
Min EPS beat(4)-60.78%
Max EPS beat(4)153.55%
EPS beat(8)4
Avg EPS beat(8)-4.45%
EPS beat(12)5
Avg EPS beat(12)-1.61%
EPS beat(16)6
Avg EPS beat(16)-0.1%
Revenue beat(2)2
Avg Revenue beat(2)29.81%
Min Revenue beat(2)20.66%
Max Revenue beat(2)38.97%
Revenue beat(4)4
Avg Revenue beat(4)18.27%
Min Revenue beat(4)6.16%
Max Revenue beat(4)38.97%
Revenue beat(8)7
Avg Revenue beat(8)13.18%
Revenue beat(12)10
Avg Revenue beat(12)12.78%
Revenue beat(16)12
Avg Revenue beat(16)11.41%
PT rev (1m)0%
PT rev (3m)73.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.75%
EPS NY rev (1m)0%
EPS NY rev (3m)44.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.14 | ||
| Fwd PE | 19.89 | ||
| P/S | 2.4 | ||
| P/FCF | 21.25 | ||
| P/OCF | 17.7 | ||
| P/B | 4.41 | ||
| P/tB | 4.42 | ||
| EV/EBITDA | 14.21 |
EPS(TTM)1.54
EY3.69%
EPS(NY)2.1
Fwd EY5.03%
FCF(TTM)1.97
FCFY4.71%
OCF(TTM)2.36
OCFY5.65%
SpS17.42
BVpS9.47
TBVpS9.46
PEG (NY)0.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.59% | ||
| ROE | 16.87% | ||
| ROCE | 19.42% | ||
| ROIC | 15.13% | ||
| ROICexc | 18.49% | ||
| ROICexgc | 18.51% | ||
| OM | 14.71% | ||
| PM (TTM) | 9.17% | ||
| GM | 28.25% | ||
| FCFM | 11.29% |
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
ROICexc(3y)13.33%
ROICexc(5y)16.93%
ROICexgc(3y)13.36%
ROICexgc(5y)17.03%
ROCE(3y)15.15%
ROCE(5y)17.2%
ROICexcg growth 3Y11.8%
ROICexcg growth 5Y-12.49%
ROICexc growth 3Y11.98%
ROICexc growth 5Y-12.32%
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
F-Score5
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.1 | ||
| Debt/EBITDA | 1.16 | ||
| Cap/Depr | 108.63% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | 14.48 | ||
| Cash Conversion | 80.7% | ||
| Profit Quality | 123.12% | ||
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.94 | ||
| Altman-Z | 6.36 |
F-Score5
WACC8.7%
ROIC/WACC1.74
Cap/Depr(3y)140.73%
Cap/Depr(5y)342.39%
Cap/Sales(3y)2.61%
Cap/Sales(5y)6.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.18%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%541.18%
EPS Next Y229.03%
EPS Next 2Y84.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%24.74%
Revenue Next Year23.48%
Revenue Next 2Y12.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.62%
EBIT growth 3Y16.56%
EBIT growth 5Y7.53%
EBIT Next Year56.92%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y493.37%
FCF growth 3YN/A
FCF growth 5Y22%
OCF growth 1Y1266.06%
OCF growth 3YN/A
OCF growth 5Y13.23%